Skip to main content
. 2021 Dec 1;11:750657. doi: 10.3389/fonc.2021.750657

Table 1.

Efficacy of ICIs in NSCLS with ALK mutations.

Reference Characteristics ORR, % mPFS, months mOS, months since start of ICI
Mazieres J., et al. (31) ALK (n=23) 0 2.5 17
Gainor JF.,et al. (32) ALK (n=6) 0
Jahanzeb M., et al. (33) ALK (n=83) 2.34
Gadgeel SM. et al. (34) ALK (n=7) 28.6% 2.9 2.9

ICIs, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; ORR, overall response rate; mPFS-median progression-free survival; mOS, median overall survival.